The European Medicines Agency (EMA) announced today, Tuesday, that it will issue its opinion on Tuesday regarding the Janssen vaccine against Covid-19, which has been suspended for use in the United States and Europe due to its association with blood clots.
The Amsterdam-based agency announced today that it will provide a “virtual press conference on safety assessment findings” for the Johnson & Johnson vaccine.
The press conference will be held at 16:00 (Portuguese time).
Portugal has already received its first 31,200 doses of the Janssen vaccine, which will be stored until a decision is made by the European regulator on its use.
Janssen announced that, on her own initiative, she will delay the distribution of the drug in Europe due to the preventive suspension of her administration in the United States.
On Wednesday, the EMA had already said that the benefits of the Janssen vaccine outweighed the risks after a blood clot in the US, but it sent the decision to next week.
Currently, four vaccines have been approved in the European Union: Pfizer / BioNTech, Moderna, Vaxzevria (the new name for the AstraZeneca vaccine), and Janssen.
The Covid-19 pandemic has killed at least 298,7891 people around the world, resulting in more than 139 million cases, according to a report issued by Agence France-Presse.
In Portugal, 16,937 people died out of 829,911 confirmed cases, according to the latest bulletin issued by the General Directorate of Health.
Andrea Hargraves is a contributor to Brytfmonline.com, covering a broad range of topics including news, politics, business, technology, sports, entertainment, and lifestyle. She is committed to delivering clear, accurate, and reader-focused reporting that helps audiences stay informed about current events and emerging developments. Andrea’s work emphasizes useful information, balanced coverage, and stories that matter to everyday readers, making complex topics accessible and relevant to a wide audience.